The results indicate that by Augment has a comparable treatment outcome while producing less pain and potential morbidity than traditional autograft bone harvesting and transplantation.
Read BioMemetic’s release on its Augment Bone Graft.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
